Patent ID: 8591944

Claim:
A pharmaceutical composition in unit dosage form for oral administration, said composition comprising from about 20 mg to about 250 mg of substantially amorphous 1-(4-benzhydrylpiperazine-1-yl)-3,3-diphenylpropan-1-one and a pharmaceutically acceptable matrix polymer, wherein said pharmaceutical composition comprises a solid dispersion of said 1-(4-benzhydrylpiperazine-1-yl)-3,3-diphenylpropan-1-one and said pharmaceutically acceptable matrix polymer, wherein said pharmaceutically acceptable matrix polymer comprises a polymer selected from the group consisting of a cellulose derivative, a polyacrylate, a polyvinyl pyrrolidone, a polyvinyl acetate, and a copolymer of a polyvinyl pyrrolidone and a polyvinyl acetate, wherein the weight ratio of said 1-(4-benzhydrylpiperazine-1-yl)-3,3-diphenylpropan-1-one to said pharmaceutically acceptable matrix polymer is from about 1:6 to about 1:1.5.